Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs
Active, not recruitingOBSERVATIONAL
Enrollment
30
Participants
Timeline
Start Date
October 10, 2022
Primary Completion Date
March 31, 2024
Study Completion Date
December 31, 2025
Conditions
Non Small Cell Lung Cancer
Trial Locations (1)
40138
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna
All Listed Sponsors
lead
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
NCT06863818 - Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs | Biotech Hunter | Biotech Hunter